| ORIGINAL ARTICLE |
|
| Year : 2018 | Volume
: 9
| Issue : 4 | Page : 165-169 |
|
|
Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot
Kiran Gordhanbhai Piparva, Gaurav Jansari, Anil P Singh
Department of Pharmacology, P.D.U. Government Medical College, Rajkot, Gujarat, India
Correspondence Address:
Dr. Kiran Gordhanbhai Piparva
12/15 Manhar Plot, “Panchjanya”, Rajkot - 360 002, Gujarat
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/picr.PICR_165_17
|
|
|
Background: The emergence of drug-resistant mycobacteria becomes a significant public health problem globally creating an obstacle to effective tuberculosis (TB) control. Gujarat, Maharashtra, and Andhra Pradesh DRS survey estimated that the proportion of multidrug-resistant TB (MDR-TB) is 2.1% (in new TB cases) and 15% (in previously treated cases). Programmatic management of MDR-TB implemented under Revised National Tuberculosis Control Programme in India in 2007.
Objectives: The objective of this study is to evaluate treatment outcome and adverse drug reactions (ADRs) of category IV.
Materials and Methods: A total of 108 MDR-TB patients were analyzed retrospectively who registered and received treatment during the year of 2014 and 2015 at district TB centre, Rajkot. MDR patients who died or transferred out or defaulter before completion of intensive phase were excluded from the analysis.
Results: Of total 108 patients majority patients (64.81%) were in young (20–39 years) with m:f: 2:1. All MDR-TB patients were retreated cases and 69.44% were “undernutrition category”. Culture conversion rate was 86.91% at 4 months of treatment. Cure rate was 50.93% while defaulter rate and died rate was same (17.59%). Failure rate was 18.51%. Weight improvement was significantly associated with cure rate. The incidence of ADR was 32.71%. Most frequent ADRs were related to gastrointestinal system (34.42%), ototoxicity (13.11%), and central nervous system (8.1%). Aminoglycosides, cycloserine, and ethambutol were discontinued due to ADR. Majority ADRs (77.04%) were “possible” category by causality assessment and “mild” in severity assessment. Ototoxicity was only severe ADRs observed.
Conclusion: Cure rate was improved than previous years at same center. Attention should be paid for defaulters. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
